Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.
Publication
, Journal Article
Cooper, LB; Hernandez, AF
Published in: Eur J Heart Fail
August 2018
Duke Scholars
Published In
Eur J Heart Fail
DOI
EISSN
1879-0844
Publication Date
August 2018
Volume
20
Issue
8
Start / End Page
1227 / 1229
Location
England
Related Subject Headings
- Spironolactone
- Receptors, Mineralocorticoid
- Mineralocorticoid Receptor Antagonists
- Incidence
- Hyperkalemia
- Humans
- Heart Failure
- Cardiovascular System & Hematology
- Aldosterone
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Cooper, L. B., & Hernandez, A. F. (2018). Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. Eur J Heart Fail, 20(8), 1227–1229. https://doi.org/10.1002/ejhf.1221
Cooper, Lauren B., and Adrian F. Hernandez. “Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.” Eur J Heart Fail 20, no. 8 (August 2018): 1227–29. https://doi.org/10.1002/ejhf.1221.
Cooper LB, Hernandez AF. Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. Eur J Heart Fail. 2018 Aug;20(8):1227–9.
Cooper, Lauren B., and Adrian F. Hernandez. “Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.” Eur J Heart Fail, vol. 20, no. 8, Aug. 2018, pp. 1227–29. Pubmed, doi:10.1002/ejhf.1221.
Cooper LB, Hernandez AF. Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. Eur J Heart Fail. 2018 Aug;20(8):1227–1229.
Published In
Eur J Heart Fail
DOI
EISSN
1879-0844
Publication Date
August 2018
Volume
20
Issue
8
Start / End Page
1227 / 1229
Location
England
Related Subject Headings
- Spironolactone
- Receptors, Mineralocorticoid
- Mineralocorticoid Receptor Antagonists
- Incidence
- Hyperkalemia
- Humans
- Heart Failure
- Cardiovascular System & Hematology
- Aldosterone
- 3201 Cardiovascular medicine and haematology